All News

Sephin1 found to protect oligodendrocytes, axons, and myelin, as well as reduce central nervous system inflammation in multiple sclerosis.

Although many pharmacists are divided when it comes to their job satisfaction, most of them are currently happy with their compensation, according to a recent Pharmacy Times® Salary and Job Satisfaction Survey.

The collaborating drug companies cut prices in an effort to make their drugs more accessible.

Warning letters and online advisory letters were posted to the agency's website for 58 products, mostly dietary supplements.

The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.

The supplemental Biologics License Application was filed based on positive overall survival data from a phase 3 clinical trial for pembrolizumab in the treatment of recurrent or metastatic head and neck squamous cell carcinoma.

There are currently no FDA-approved therapies for the prevention or treatment of acute graft-versus-host disease.

Immunotherapy may become a viable option for patients with cancer infected with HIV.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Can you solve why this lady had a mysterious heart attack?

Analysis finds universal screening for hepatitis C virus infection would be cost effective and provide greater benefit than the currently recommended birth cohort screening.

Pulmatrix is set to launch a clinical investigation on the product in 2019.

Researchers predict that the changing nature of the epidemic, driven by the illegal use of opioids such as heroin and fentanyl, has reduced the potential impact of programs that target prescription opioids.

Throughout the country, 47 states and Puerto Rico experienced this in the week ended February 2.

The program aims to reduce the amount of illegal or suspect prescription drugs distributed throughout the United States.

The study is the longest observation to date of patients with advanced Merkel cell carcinoma receiving first-line pembrolizumab.

The risks are too high for the pharmacy to be cavalier regarding compliance with antifraud laws.

A recent model by Massachusetts General Hospital projects that without proper policy, public health and health care delivery efforts, the opioid overdose epidemic will increase.

Following recent drug pricing hearings on Capitol Hill, the Trump Administration proposed a rule targeting the prescription drug rebate system.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Patients with chronic obstructive pulmonary disease (COPD) who receive a flu vaccine are significantly less likely to be hospitalized with influenza.

Top news of the day across the health care landscape.

Pharmacy Times Continuing Education™ (PTCE), a leader in continuing education for retail, health-system, managed care and specialty pharmacists, has announced the ninth annual Directions in Pharmacy® continuing education conference series, which will take place in 4 major cities across the United States in spring 2019.

To reduce the likelihood of people giving up on PrEP because of difficulty committing to multiple annual visits, a team of investigators created PrEP@Home, a home-based monitoring system that will allow people on the PrEP regimen to meet with their health care providers just once a year, its creators say.

A recent study analyzed how health systems utilize and integrate virtual care into their daily practice.

Under the rule, prescription rebates may be passed directly to patients at the pharmacy counter, effectively creating a new safe harbor designed for price reductions at the point of sale.

The findings are further evidence of the impact of an active lifestyle on physical health.

Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.